Roger Sidhu - 20 Sep 2021 Form 4 Insider Report for Brooklyn ImmunoTherapeutics, Inc. (ERNA)

Role: Chief Medical Officer
Signature: /s/Bella Zaslavsky, Attorney-in-Fact for Roger Sidhu
Issuer symbol: ERNA
Transactions as of: 20 Sep 2021
Net transactions value: $0
Form type: 4
Filing time: 22 Sep 2021, 16:57:24 UTC
Next filing: 17 Mar 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ERNA	Stock Option	Award	$0	+161,300		$0.000000	161,300	20 Sep 2021	Common Stock	161,300	$9.96	Direct	F1
transaction	ERNA	Restricted Stock Unit	Award	$0	+80,650		$0.000000	80,650	20 Sep 2021	Common Stock	80,650		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option vests and becomes exercisable over four years, with twenty-five percent of the shares covered thereby vesting on September 20, 2022, and 1/36 of the remaining shares covered thereby vesting on the twentieth day of each calendar month from October 2022 through September 20, 2025, subject to continued service through each vesting date.
F2	Each restricted stock unit represents a contingent right to receive one share of common stock.
F3	The RSU Grant vests and becomes exercisable in four equal installments on September 20 of each of 2022, 2023, 2024 and 2025, provided that it shall vest in full immediately prior to a change in control (as defined in Dr. Sidhu's Executive Employment Agreement, effective September 20, 2021), subject to continued service through each vesting date.

Remarks:

Chief Medical Officer